Compare MNSB & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MNSB | CCCC |
|---|---|---|
| Founded | 2003 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 148.8M | 177.4M |
| IPO Year | N/A | 2020 |
| Metric | MNSB | CCCC |
|---|---|---|
| Price | $22.61 | $1.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.25 |
| AVG Volume (30 Days) | 65.6K | ★ 1.4M |
| Earning Date | 01-26-2026 | 02-27-2026 |
| Dividend Yield | ★ 1.80% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.76 | N/A |
| Revenue | ★ $73,642,000.00 | $30,108,000.00 |
| Revenue This Year | $0.46 | N/A |
| Revenue Next Year | $4.14 | N/A |
| P/E Ratio | $12.67 | ★ N/A |
| Revenue Growth | ★ 24.68 | N/A |
| 52 Week Low | $15.00 | $1.09 |
| 52 Week High | $23.44 | $3.65 |
| Indicator | MNSB | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 63.03 | 41.56 |
| Support Level | $22.07 | $1.74 |
| Resistance Level | $22.86 | $1.97 |
| Average True Range (ATR) | 0.56 | 0.13 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 68.98 | 28.87 |
MainStreet Bancshares Inc is a bank holding company. It is focused on serving the borrowing, cash management and depository needs of small to medium-sized businesses, and professional practices and retail customers. The bank's products and services include business and consumer checking, premium interest-bearing checking, business account analysis, savings, certificates of deposit and other depository services, as well as a broad array of commercial, real estate and consumer loans.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.